Citations

Clear

9 citation(s) found for "Mo, Xianming".

Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort
Yanagihara, Ted K. , Dawson, Laura A., Yu, Jeong Il, Lawrence, Theodore S. , Kim, T S, Yan, Michael, Iwata, Hiromitsu , Nabavizadeh, Nima , Apisarnthanarax, Smith , Dunne, Emma M., Lock, Michael , Chuong, Michael D., Chiang, Chi Leung, Katoh, Norio , Sioshansi, Shirin, Numata, Kazushi, Liu, Howard , Wakatsuki, Masaru , Chen, YiXing, Pollom, Erqi L., Gkika, Eleni , Dutta, Debnarayan , Hajj, Carla , Hallemeier, Christopher L. , Feldman, Aharon, Romero, Alejandra Méndèz , Tan, Xianming , Tepper, Joel E. , Torres, Ferràn , Bergman, Alanah M., Crane, Christopher, Cuneo, Kyle C., Grindrod, Natalie, Grosu, Anca-Ligia, Far, R. El, Funaoka, Akihiro, Gilbert, Marissa, Itasaka, Satoshi , Lee, Sung Uk , Mases, Joel , Ogino, Hiroyuki , Qu, Vera , Park, Hee Chul, Rahmani, Ramtin, Shing, Lee Ann, Stanescu, Teodor, Thonglert, Kanokphorn , Toom, Wilhelm den , Uchinami, Yusuke , Zeng, Zhaochong, Moon, Andrew M , Yanagihara, Ted K , Lawrence, Theodore S , Kim, Tae Hyun , Iwata, Hiromitsu , Nabavizadeh, Nima , Apisarnthanarax, Smith , Lock, Michael I , Chuong, Michael , Chiang, Chi Leung , Scorsetti, Marta , Katoh, Norio , Liu, Howard Yu-Hao , Iwamoto, Hideki , Pollom, Erqi Liu , Gkika, Eleni , Jabbour, Salma K , Munoz-Schuffenegger, Pablo , Dutta, Debnarayan , Hajj, Carla , Ueno, Masayuki , Hallemeier, Christopher Leigh , Feldman, Aharon M , Méndèz Romero, Alejandra , Tan, Xianming , Tepper, Joel E , Torres, Ferran , Reig, Maria , Dawson, Laura A. , Yu, Jeong Il , Dunne, Emma Maria , Chuong, Michael D. , Numata, Kazushi , Mollà, Meritxell , Crane, Christopher H. , Cuneo, Kyle Clifford , Grindrod, Natalie , Franzese, Ciro , Gilbert, Marissa, Lee, Yoo Young , Lee, Ann‐Shing, Shirono, Tomotake , Stanescu, Teo

Mayo Clinic

Journal of Clinical Oncology | May 15, 2026 | Volume: 44 | Issue: 19 | Pages: 1784-1797

10.1200/jco-25-02399 | PMID 42139645 Get It

PURPOSE External beam radiation therapy (EBRT) has gained delayed acceptance as a recommended first-line treatment modality for patients with hepatocellular carcinoma (HCC), given limited evidence that it improves overall survival (OS). We analyzed individual patient data (IPD) from an international cohort to assess OS among patients with HCC treated with EBRT. METHODS We performed a systematic review of publications that assessed EBRT, met prespecified technical standards for HCC, and reported OS (search date December 15, 2022). Corresponding authors were invited to submit IPD for the study. We performed Kaplan-Meier survival analyses to determine OS and restricted mean survival time (RMST) stratified by Barcelona Clinic Liver Cancer (BCLC) stage and treatment status (ie, treatment-naïve and experienced). We performed random effects Cox proportional hazards modeling to assess clinical characteristics associated with OS. RESULTS Data were provided on 4,913 patients treated with EBRT with a median follow-up time of 5.0 years. The median OS was 6.8 years (95% CI, 5.7 to 8.7) for BCLC-0 and 4.6 years (95% CI, 4.1 to 5.1) for BCLC-A. Among treatment-naïve patients, the median OS was not reached (95% CI, 8.6 to not reached) for BCLC-0 and was 5.4 years (95% CI, 4.5 to 6.7) for BCLC-A. In multivariable models, more advanced BCLC stage, higher tumor burden, worse performance status, and Child-Pugh class B or C were associated with a higher risk of mortality. Ablative radiation dose and more recent year of treatment were associated with a reduced risk of death. CONCLUSION To our knowledge, this study represents the largest multinational cohort of patients with HCC treated with EBRT. OS outcomes with EBRT for very early- and early-stage HCC appear to be comparable with resection, thermal ablation, and other ablative locoregional therapies. These data support the inclusion of EBRT in the BCLC HCC clinical decision-making process.
COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial
Habtehyimer, Feben , Zhu, Xianming , Redd, Andrew D. , Patel, Eshan U. , Laeyendecker, Oliver , Gniadek, Thomas J. , Fernández, Reinaldo E. , Baker, Owen R. , Ram, Malathi , Cachay, Edward R. , Fukuta, Yuriko , Gerber, Jonathan M. , Heath, Sonya L. , Huamán, Moisés A. , Blair, Janis E. , Cruser, Daniel, Forthal, Donald N. , Hammitt, Laura L. , Patel, Bela , Abinante, Matthew, Oei, Kevin , Cluzet, Valerie , Cordisco, Marie Elena , Greenblatt, Benjamin, Rausch, William, Shade, David , Gawad, Amy L., Bloch, Evan M. , Patel, Eshan U , Laeyendecker, Oliver , Forthal, Donald N , Sutcliffe, Catherine G , Klein, Sabra L , Pekosz, Andrew , Casadevall, Arturo , Tobian, Aaron A R , Sullivan, David J , Huaman, Moises A , Zhu, Xianming , Gebo, Kelly A , Abraham, Alison G. , Currier, Judith S. , Meisenberg, Barry R. , Levine, Adam C , Shenoy, Aarthi , Anjan, Shweta , Kassaye, Seble , Mosnaim, Giselle S , Paxton, James H , Raval, Jay S. , Shoham, Shmuel , Casadevall, Arturo , Hanley, Daniel F. , Tobian, Aaron A.R. , Sullivan, David

Mayo Clinic

Microbiology Spectrum | November 27, 2023 | Volume: 12 | Issue: 1 | Pages: No page available

10.1128/spectrum.03286-23 | PMID 38009954 Get It

ABSTRACT Early COVID-19 convalescent plasma (CCP) transfusion to outpatients with COVID-19 decreases progression to hospitalization, but the mechanism of how CCP reduces severity is unknown. Among 882 COVID-19 participants transfused with CCP or control plasma in a randomized controlled trial, 21 cytokines and chemokines were measured using electrochemiluminescence assays. Wilcoxon rank sum tests were used to evaluate the difference between early (transfused within 5 days of symptom onset) CCP vs early control plasma and late (transfused 6–9 days after symptom onset) CCP vs late control plasma at each visit. Linear mixed-effect models were used to assess the difference in the slope of cytokine change. Median cytokine and chemokine levels were similar between the early CCP and early control groups pre-transfusion. At the day 14 visit, only the median IL-6 ( P = 0.014) and IL-16 ( P = 0.036) levels were lower in the early CCP group compared to the early control group, but these differences were not statistically significant after correcting for multiple comparisons (requiring P < 0.0024). IL-6 levels decreased significantly faster in the early CCP group from screening to the day 14 visit compared to the early control group ( P < 0.001). No difference was observed in the slope of cytokine change from screening to day 90 between early CCP and early control groups. Late control and late CCP arms showed similar cytokine and chemokine levels through study follow-up. One mechanism by which early CCP transfusion reduces hospitalization may be by decreasing IL-6 levels, as the reduction is associated with better recovery from COVID-19. IMPORTANCE This study examined the role that cytokines may have played in the beneficial outcomes found when outpatient individuals infected with SARS-CoV-2 were transfused with COVID-19 convalescent plasma (CCP) early in their infection. We found that the pro-inflammatory cytokine IL-6 decreased significantly faster in patients treated early with CCP. Participants with COVID-19 treated with CCP later in the infection did not have the same effect. This decrease in IL-6 levels after early CCP treatment suggests a possible role of inflammation in COVID-19 progression. The evidence of IL-6 involvement brings insight into the possible mechanisms involved in CCP treatment mitigating SARS-CoV-2 severity.
401. Risk of Post-COVID Conditions Correlates with IL-6 Plasma Levels and Is Reduced by Early Antibody Therapy
Fukuta, Yuriko , Heath, Sonya L. , Baksh, Sheriza , Habtehyimer, Feben , Shade, David , Ruff, Jessica E. , Ram, Malathi , Fernández, Reinaldo E. , Baker, Owen R. , Cachay, Edward R. , Gerber, Jonathan M. , Hammitt, Laura L. , Forthal, Donald N. , Patel, Bela, Gniadek, Thomas J. , Blair, Janis E. , Lane, Karen , McBee, Nichol , Gawad, Amy L., Das, Piyali, Bloch, Evan M. , Gebo, Kelly A , Zhu, Xianming , Abraham, Alison G. , Laeyendecker, Oliver , Patel, Eshan U. , Shoham, Shmuel , Currier, Judith S. , Meisenberg, Barry R. , Huamán, Moisés A. , Levine, Adam C , Mosnaim, Giselle S , Paxton, James H , Raval, Jay S. , Sutcliffe, Catherine G , Anjan, Shweta , Kassaye, Seble , Klein, Sabra L , Pekosz, Andrew , Hanley, Daniel F. , Casadevall, Arturo , Tobian, Aaron A.R. , Sullivan, David

Mayo Clinic

Open Forum Infectious Diseases | November 27, 2023 | Volume: 10 | Issue: Supplement_2 | Pages: No page available

10.1093/ofid/ofad500.471 Get It

Abstract Background Post-COVID conditions (PCC) are common, and risk factors include older age and female sex. While high interleukin (IL)-6 and C-reactive protein are associated with more severe disease, it is unclear whether other cytokines are associated with PCC. This study was performed to identify factors associated with PCC development. Methods The Convalescent Plasma to Limit SARS-CoV-2 Associated Complications (CSSC-004) trial was a double-blind, multi-center, randomized, controlled trial comparing the use of COVID-19 convalescent plasma (CCP) to control plasma for the prevention of hospitalization among COVID-19 outpatients. Among 882 individuals participating in the trial with available biospecimens and symptom data, the association between early COVID-19 treatment, cytokine levels and PCC was evaluated. Cytokine and chemokine levels were assessed at baseline, day 14 and day 90 using a multiplexed sandwich immuosassay. Presence of any PCC symptom was assessed at day 90. Associations between COVID-19 treatment, cytokine levels and PCC were examined using multivariate logistic regression models. Results Baseline characteristics were similar by trial treatment group (Figure 1). At day 90, 292 (33.1%) participants had PCC. The most common symptoms were fatigue (14.5%), anosmia (14.5%), and ageusia (10.0%). Levels of most cytokines decreased over time (Figure 2). Six pro-inflammatory cytokines especially IL-6 were elevated at baseline among those with PCC (Figure 3). In multivariable analysis, female sex (adjusted odds ratio [AOR]=2.70[1.93-3.81]), age 50 or greater (AOR=1.32[1.17-1.50]), and elevated baseline IL-6 (AOR=1.59[1.02-2.47]) were associated with development of PCC, whereas race, obesity, vaccine status and diabetes were not. Those who received early CCP treatment (&lt;5 days after symptom onset) compared to late CCP treatment had statistically significant lower odds of PCC (AOR=0.60 [0.38-0.95]). Conclusion This study showed high prevalence of PCC symptoms at day 90, particularly among those with higher baseline levels of IL-6 or who did not receive early CCP treatment. The potential utility of IL-6 modulation as a therapeutic intervention among individuals as higher risk for PCC should be studied. Disclosures Kelly Gebo, MD, MPH, Pfizer: Advisor/Consultant|Spark HealthCare: Advisor/Consultant Sonya L. Heath, MD, Pfizer: Data Monitoring Committee/DSMB Shmuel Shoham, MD, adagio: Advisor/Consultant|Adamis: Advisor/Consultant|ansun: Grant/Research Support|Avir Pharma: Honoraria|cidara: Grant/Research Support|F2G: Grant/Research Support|Immunome: Advisor/Consultant|Karius: Honoraria|Scynexis: Advisor/Consultant|zeteo: Grant/Research Support Judith S. Currier, M.D., MSc, Merck and Company: Advisor/Consultant|Merck and Company: Honoraria Moises A. Huaman, MD, MSc, AN2 Therapeutics Inc: Grant/Research Support|Gilead Sciences Inc: Grant/Research Support|Insmed Inc: Grant/Research Support Jay S. Raval, MD, Sanofi Genzyme: Advisor/Consultant Arturo Casadevall, MD, PhD, Ortho Diagnostics: Speakers Bureau|Sabtherapeutics: Advisor/Consultant
Early antibody treatment, inflammation, and risk of post-COVID conditions
Heath, Sonya L. , Fukuta, Yuriko , Zhu, Xianming , Baksh, Sheriza , Abraham, Allison G., Habtehyimer, Feben , Shade, David , Ruff, Jessica E. , Ram, Malathi , Laeyendecker, Oliver , Fernández, Reinaldo E. , Patel, Eshan U. , Baker, Owen R. , Cachay, Edward R. , Gerber, Jonathan M. , Forthal, Donald N. , Hammitt, Laura L. , Huamán, Moisés A. , Patel, Bela , Gniadek, Thomas J. , Blair, Janis E. , Lane, Karen , McBee, Nichol , Gawad, Amy L., Das, Piyali, Bloch, Evan M. , Zhu, Xianming , Laeyendecker, Oliver , Patel, Eshan U , Forthal, Donald N , Sutcliffe, Catherine G , Klein, Sabra L , Pekosz, Andrew , Bloch, Evan M , Casadevall, Arturo , Tobian, Aaron A R , Sullivan, David J , Huaman, Moises A , Gebo, Kelly A , Shoham, Shmuel , Currier, Judith S. , Meisenberg, Barry R. , Levine, Adam C , Mosnaim, Giselle S , Paxton, James H , Raval, Jay S. , Anjan, Shweta , Kassaye, Seble , Hanley, Daniel F. , Casadevall, Arturo , Tobian, Aaron A.R. , Sullivan, David

Mayo Clinic

mBio | September 19, 2023 | Volume: 14 | Issue: 5 | Pages: No page available

10.1128/mbio.00618-23 | PMID 37724870 Get It

Post-COVID conditions (PCCs) are common and have significant morbidity. Risk factors for PCC include advancing age, female sex, obesity, and diabetes mellitus. Little is known about treatment, inflammation, and PCC. Among 882 individuals with confirmed SARS-CoV-2 infection participating in a randomized trial of COVID-19 convalescent plasma (CCP) vs control plasma with available biospecimens and symptom data, the association between early CCP treatment, cytokine levels, and PCC was evaluated. Cytokine and chemokine levels were assessed at baseline, day 14, and day 90 using a multiplexed sandwich immunoassay (Meso Scale Discovery). Presence of any self-reported PCC symptoms was assessed at day 90. Associations between CCP treatment, cytokine levels, and PCC were examined using multivariate logistic regression models. One third of the 882 participants had day 90 PCC symptoms, with fatigue (14.5%) and anosmia (14.5%) being most common. Cytokine levels decreased from baseline to day 90. In a multivariable analysis, female sex (adjusted odds ratio [AOR] = 2.69 [1.93–3.81]), older age (AOR = 1.32 [1.17–1.50]), and elevated baseline levels of IL-6 (AOR = 1.59 [1.02–2.47]) were independently associated with development of PCC. Those who received early CCP treatment (≤5 days after symptom onset) compared to late CCP treatment had statistically significant lower odds of PCC. IMPORTANCE Approximately 20% of individuals infected with SARS-CoV-2 experienced long-term health effects, as defined PCC. However, it is unknown if there are any early biomarkers associated with PCC or whether early intervention treatments may decrease the risk of PCC. In a secondary analysis of a randomized clinical trial, this study demonstrates that among outpatients with SARS-CoV-2, increased IL-6 at time of infection is associated with increased odds of PCC. In addition, among individuals treated early, within 5 days of symptom onset, with COVID-19 convalescent plasma, there was a trend for decreased odds of PCC after adjusting for other demographic and clinical characteristics. Future treatment studies should be considered to evaluate the effect of early treatment and anti-IL-6 therapies on PCC development.
SNX27-FERM-SNX1 complex structure rationalizes divergent trafficking pathways by SNX17 and SNX27
Yong, Xin, Ham, Hyoungjun , Liu, Zhe , Ren, Jie , Zhang, Zhen , Zhou, Yifei, Yang, Qin , Mo, Xianming , Billadeau, Daniel D. , Jia, Da , Yang, Qin , Mo, Xianming , Hu, Junjie , Jia, Da , Yong, Xin, Zhao, Lin , Hu, Wenfeng , Sun, Qingxiang

Mayo Clinic

Proceedings of the National Academy of Sciences | August 30, 2021 | Volume: 118 | Issue: 36 | Pages: No page available

10.1073/pnas.2105510118 | PMID 34462354 Get It

Significance The sorting nexin proteins are critical for endosomal trafficking and signaling. SNX17 and SNX27 are two SNX proteins displaying high similarity in domain structure, including a common FERM domain; however, they mediate distinct endocytic recycling pathways. We now solve this mystery by demonstrating that the FERM domains of SNX17 and SNX27 have different functions. Whereas the FERM domain of SNX17 recognizes the NPxY/NxxY motif, the same domain in SNX27 binds to a novel “DLF” motif within the N termini of SNX1/2. The interaction between SNX27 and SNX1/2 not only helps efficient retrieval of multiple cargoes but also promotes endosomal recruitment of SNX27. We further demonstrate that the SNX27–SNX1/2 interaction is crucial to neuronal growth and brain development in zebrafish.
Phosphorylation of SNX27 by MAPK11/14 links cellular stress–signaling pathways with endocytic recycling
Mao, Lejiao , Liao, Chenyi , Qin, Jiao , Gong, Yanqiu , Zhou, Yifei, Liu, Zhe , Deng, Huaqing , Deng, Wankun , Mo, Xianming , Xue, Yu , Billadeau, Daniel D. , Dai, Lunzhi , Li, Guohui , Jia, Da , Jia, Da , Li, Shasha , Sun, Qingxiang

Mayo Clinic

Journal of Cell Biology | February 21, 2021 | Volume: 220 | Issue: 4 | Pages: No page available

10.1083/jcb.202010048 | PMID 33605979 Get It

Endocytosed proteins can be delivered to lysosomes for degradation or recycled to either the trans-Golgi network or the plasma membrane. It remains poorly understood how the recycling versus degradation of cargoes is determined. Here, we show that multiple extracellular stimuli, including starvation, LPS, IL-6, and EGF treatment, can strongly inhibit endocytic recycling of multiple cargoes through the activation of MAPK11/14. The stress-induced kinases in turn directly phosphorylate SNX27, a key regulator of endocytic recycling, at serine 51 (Ser51). Phosphorylation of SNX27 at Ser51 alters the conformation of its cargo-binding pocket and decreases the interaction between SNX27 and cargo proteins, thereby inhibiting endocytic recycling. Our study indicates that endocytic recycling is highly dynamic and can crosstalk with cellular stress–signaling pathways. Suppression of endocytic recycling and enhancement of receptor lysosomal degradation serve as new mechanisms for cells to cope with stress and save energy.
Structural and functional studies of TBC1D23 C-terminal domain provide a link between endosomal trafficking and PCH
Huang, Wenjie , Liu, Zhe , Yang, Fan , Zhou, Huan , Yong, Xin, Yang, Xiaoyu , Zhou, Yifei, Xue, Lijia, Liu, Dingdong, Meng, Wentong , Zhang, Wenming , Zhang, Xiaohu , Shen, Xiaofei , Li, Li , Ma, Cong , Billadeau, Daniel D. , Mo, Xianming , Jia, Da , Ma, Cong , Jia, Da , Yong, Xin, Zhang, Yihong, Zhang, Wenming, Sun, Qingxiang , Wei, Yuquan

Mayo Clinic

Proceedings of the National Academy of Sciences | October 17, 2019 | Volume: 116 | Issue: 45 | Pages: 22598-22608

10.1073/pnas.1909316116 | PMID 31624125 Get It

Pontocerebellar hypoplasia (PCH) is a group of neurological disorders that affect the development of the brain, in particular, the pons and cerebellum. Homozygous mutations of TBC1D23 have been found recently to lead to PCH; however, the underlying molecular mechanisms remain unclear. Here, we show that the crystal structure of the TBC1D23 C-terminal domain adopts a Pleckstrin homology domain fold and selectively binds to phosphoinositides, in particular, PtdIns(4)P, through one surface while binding FAM21 via the opposite surface. Mutation of key residues of TBC1D23 or FAM21 selectively disrupts the endosomal vesicular trafficking toward the Trans-Golgi Network. Finally, using the zebrafish model, we show that PCH patient-derived mutants, impacting either phosphoinositide binding or FAM21 binding, lead to abnormal neuronal growth and brain development. Taken together, our data provide a molecular basis for the interaction between TBC1D23 and FAM21, and suggest a plausible role for PtdIns(4)P in the TBC1D23-mediating endosome-to-TGN trafficking pathway. Defects in this trafficking pathway are, at least partially, responsible for the pathogenesis of certain types of PCH.
Phosphatidylserine (PS) Is Exposed in Choroidal Neovascular Endothelium: PS-Targeting Antibodies Inhibit Choroidal Angiogenesis In Vivo and Ex Vivo
Aredo, Bogale, Zhong, Xin , Pulido, José S. , Wang, Shusheng , He, Yu-Guang, Huang, Xianming , Brekken, Rolf A. , Ufret-Vincenty, Rafael , Li, Tao , Zhang, Kaiyan

Mayo Clinic

Investigative Opthalmology & Visual Science | November 3, 2015 | Volume: 56 | Issue: 12 | Pages: 7137

10.1167/iovs.15-17302 | PMID 26529048 Get It

Phenethyl isothiocyanate inhibits androgen receptor‐regulated transcriptional activity in prostate cancer cells through suppressing PCAF
Yu, Chun-Guang, Gong, Ai‐Yu, Chen, Dongqing , Leon, Daniel Solelo, Young, Charles YF, Chen, Xianming

Mayo Clinic

Molecular Nutrition & Food Research | May 10, 2013 | Volume: 57 | Issue: 10 | Pages: 1825-1833

10.1002/mnfr.201200810 | PMID 23661605 Get It

ScopeAndrogen receptor (AR) signaling is critical for all aspects of prostate growth and tumorigenesis. The glucosinolate‐derived phenethyl isothiocyanate (PEITC) has recently been demonstrated to reduce the risk of prostate cancer (PCa) and inhibit PCa cell growth. We previously reported that p300/CBP‐associated factor (PCAF), a co‐regulator for AR, is upregulated in PCa cells through suppression of the mir‐17 gene. Here, we assessed the effects of PEITC on PCAF expression and AR‐regulated transcriptional activity in PCa cells.Methods and resultsUsing AR‐responsive LNCaP cells, we observed the inhibitory effects of PEITC on the dihydrotestosterone‐stimulated AR transcriptional activity and cell growth of PCa cells. Interestingly, overexpression of PCAF attenuated the inhibitory effects of PEITC on dihydrotestosterone‐stimulated AR transcriptional activity. Expression of PCAF was upregulated in PCa cells through suppression of miR‐17. PEITC treatment significantly decreased PCAF expression and promoted transcription of miR‐17 in LNCaP cells. Functional inhibition of miR‐17 attenuated the suppression of PCAF in cells treated by PEITC.ConclusionOur results indicate that PEITC inhibits AR‐regulated transcriptional activity and cell growth of PCa cells through miR‐17‐mediated suppression of PCAF, suggesting a new mechanism by which PEITC modulates PCa cell growth.